Sign in

NCT05675969Recruiting

Pilot Study of Microvesicles in Pre-eclamptic and Non-pre-eclamptic Women With Threatened Preterm Delivery

Study of Microvesicles in Pre-eclampsia

Source: ClinicalTrials.gov · Last updated 10 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

A large number of studies on MVs from syncytiotrophoblasts support the hypothesis of their involvement in pre-eclampsia, via their multiple effects, among others as pro-coagulant, immuno-stimulatory and anti-angiogenic factors. The main objective is to compare the total concentration of the main populations of MVs in the maternal blood of a population of pre-eclamptic patients to those of a population of non-pre-eclamptic patients.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
20 (estimated)
First submitted
28 Dec 2022
Start date
31 May 2023
Primary completion date
Dec 2025
Lead sponsor
University Hospital, Bordeaux
NCT number
NCT05675969

What you commit to

  • Study type: Interventional
  • Planned participants: 20
  • From 31 May 2023 to the primary completion date, Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patient's inability to understand the nature, risks, meaning and implications of the clinical investigation or refusal to give consent
  • Patient under legal protection.

Who the study is looking for

  • Age ≥ 18 years
  • Singleton pregnancy (or spontaneously reduced twin pregnancy before 14 SA)
  • Gestational age at inclusion between 23 and 31+6 SA
  • Collection of the patient's non-opposition
  • Affiliated or beneficiary of a social security system
  • Specifically for the non-pre-eclampsia group: non-pre-eclamptic patient hospitalized for isolated threat of preterm delivery, whatever the origin, and without clinical (absence of maternal hyperthermia defined by a maternal temperature \< 38.0°C) or biological markers of inflammation (CRP\<5)
  • Specifically for the pre-eclampsia group : diagnosis of severe pre-eclampsia before 32 weeks' gestation

Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
CHU Bordeaux
Coordinator of this site? Confirm its status
BordeauxFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.